Claims for Patent: 9,175,312

Summary for Patent: 9,175,312

Title:	Vectors harboring toxic genes, methods and uses therefor
Abstract:	The present disclosure describes nucleic acids, and viruses comprising such nucleic acids, for growing a toxic gene in an insect cell. These nucleic acids comprise a sequence encoding a toxic polypeptide, and an intron that interrupts the sequence, whereby the intron is spliced in mammalian cells but not in insect cells. Infection of mammalian cells but not insect cells with the nucleic acids or viruses can lead to expression of toxic levels of the toxic polypeptide in mammalian cells but not in insect cells. Viruses, such as an AAV or a baculovirus comprising a nucleic acid can be grown in insect cell lines in vitro and can be administered to a subject in need of therapy, such as a subject in need of cancer therapy.
Inventor(s):	Chen; Haifeng (Piedmont, CA)
Assignee:	Virovek Incorporation (Hayward, CA)
Application Number:	13/982,530
Patent Claims:	1. A nucleic acid comprising: a sequence encoding a toxic polypeptide; and an intron that interrupts the sequence, whereby the intron is spliced in mammalian cells but not in insect cells to form an mRNA that is translated to form cell-toxic levels of the toxic polypeptide in mammalian cells but not in insect cells. 2. A nucleic acid in accordance with claim 1, wherein the toxic polypeptide is selected from the group consisting of diphtheria toxin (DT-A), barnase, ricin, abrin, and Pseudomonas exotoxin. 3. A nucleic acid in accordance with claim 1, wherein the toxic polypeptide is diphtheria toxin (DT-A). 4. A nucleic acid accordance with claim 1, wherein the toxic polypeptide is a barnase polypeptide. 5. A nucleic acid in accordance with claim 1, further comprising at least one expression element operably linked to the sequence. 6. A nucleic acid in accordance with claim 5, wherein the expression element is selected from the group consisting of a promoter, an IRES, an enhancer and a combination thereof. 7. A nucleic acid in accordance with claim 5, wherein the expression element is selected from the group consisting of a CMV promoter, an AFP promoter, an AFT enhancer, an hSURV promoter, a CXCR4 promoter, an hTERT promoter, a COX2 promoter, and a CCKAR promoter. 8. A nucleic acid in accordance with claim 5, wherein the expression element is selected from the group consisting of an hSURV promoter and a CXCR4 promoter. 9. A nucleic acid in accordance with claim 1, wherein the intron is an artificial intron. 10. A nucleic acid in accordance with claim 1, wherein the intron is selected from the group consisting of a human growth hormone intron and a SV40 large T-antigen intron. 11. A nucleic acid in accordance with claim 1, comprising, in 5' to 3' order, a first ITR, a promoter, a first portion of a toxic gene, an intron, a second portion of the toxic gene, a polyadenylation signal, and a second ITR. 12. A nucleic acid in accordance with claim 11, wherein the first ITR is an AAV ITR. 13. A nucleic acid in accordance with claim 11, wherein the second ITR is an AAV ITR. 14. A nucleic acid in accordance with claim 11, wherein the promoter is selected from the group consisting of a CMV promoter, a hSURV promoter, a hCXCR4 promoter, and a hAFP promoter. 15. A nucleic acid in accordance with claim 11, wherein toxic gene encodes DT-A. 16. A nucleic acid in accordance with claim 11, wherein the toxic gene encodes Barnase. 17. A viral vector comprising the nucleic acid of claim 1, wherein the vector is selected from the group consisting of a baculovirus, a retrovirus, an adenovirus, an adeno-associated virus (AAV) and a combination thereof. 18. A viral vector in accordance with claim 17, wherein the vector is a baculovirus, an adeno-associated virus (AAV), or a combination thereof. 19. A viral vector in accordance with claim 17, wherein the vector is an adeno-associated virus (AAV). 20. A viral vector in accordance with claim 17, wherein the vector is selected from the group consisting of an AAV2 and an AAV9. 21. An insect cell in vitro comprising the nucleic acid of claim 1. 22. An insect cell in accordance with claim 21, wherein the nucleic acid is comprised by a viral genome. 23. An insect cell in accordance with claim 21, wherein the cell is stably transformed with the nucleic acid of claim 1. 24. A cell culture comprising: a plurality of cells of claim 21; and a culture medium. 25. A cell culture in accordance with claim 24, wherein unconcentrated culture medium comprises a baculovirus greater than 10.sup.6 PFU/ml. 26. A method of growing a vector comprising a toxic gene in vitro, comprising: providing a cell culture comprising insect cells; infecting or transfecting the cells with a nucleic acid of claim 1; and incubating the cells under conditions suitable for virus production.

Details for Patent 9,175,312

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26